INVIVYD, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
INVIVYD, INC. (IVVD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 1.91 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-13
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 1.31M shares, a 41.13% decline year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 602.11K shares, a 48.88% decline year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 772.05K shares, a 89.66% decline year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 1.34M shares, a 63.22% decline year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 5.51M shares, a 61.26% decline from fiscal 2024.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 14.23M shares, a 61.45% increase from fiscal 2023.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 8.81M shares.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 346.17K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.31M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 1.91M shares 10-Q · filed 2026-08-13 | 2.68M shares derived: sum of 3 quarters · filed 2026-08-13 | 4.02M shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 602.11K shares 10-Q · filed 2026-05-14 | 1.37M shares derived: sum of 2 quarters · filed 2026-05-14 | 2.72M shares derived: sum of 3 quarters · filed 2026-05-14 | 4.94M shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 772.05K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 2.12M shares derived: sum of 2 quarters · filed 2026-03-05 | 4.33M shares derived: sum of 3 quarters · filed 2026-03-05 | 5.51M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 1.34M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 3.56M shares derived: sum of 2 quarters · filed 2025-11-06 | 4.74M shares 10-Q · filed 2025-11-06 | 12.21M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 2.22M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 3.39M shares 10-Q · filed 2025-08-14 | 10.86M shares derived: sum of 3 quarters · filed 2025-08-14 | 14.52M shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 1.18M shares 10-Q · filed 2025-05-15 | 8.64M shares derived: sum of 2 quarters · filed 2025-05-15 | 12.30M shares derived: sum of 3 quarters · filed 2025-05-15 | 15.06M shares derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | 7.47M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 11.12M shares derived: sum of 2 quarters · filed 2025-03-20 | 13.88M shares derived: sum of 3 quarters · filed 2025-03-20 | 14.23M shares 10-K · filed 2025-03-20 |
| 2024-09-30 | 3.66M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 6.41M shares derived: sum of 2 quarters · filed 2024-11-14 | 6.76M shares 10-Q · filed 2024-11-14 | 9.32M shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 2.76M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 3.10M shares 10-Q · filed 2024-08-14 | 5.66M shares derived: sum of 3 quarters · filed 2024-08-14 | 6.56M shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 348.48K shares 10-Q · filed 2024-05-09 | 2.91M shares derived: sum of 2 quarters · filed 2024-05-09 | 3.80M shares derived: sum of 3 quarters · filed 2024-05-09 | 7.16M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 2.56M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 3.46M shares derived: sum of 2 quarters · filed 2024-03-28 | 6.81M shares derived: sum of 3 quarters · filed 2024-03-28 | 8.81M shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 897.61K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 4.26M shares derived: sum of 2 quarters · filed 2023-11-09 | 6.25M shares 10-Q · filed 2023-11-09 | 8.40M shares derived: sum of 4 quarters · filed 2024-02-09 |
| 2023-06-30 | 3.36M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 5.36M shares 10-Q · filed 2023-08-10 | 7.50M shares derived: sum of 3 quarters · filed 2024-02-09 | 7.95M shares derived: sum of 4 quarters · filed 2024-02-09 |
| 2023-03-31 | 2.00M shares 10-Q · filed 2023-05-11 | 4.14M shares derived: sum of 2 quarters · filed 2024-02-09 | 4.59M shares derived: sum of 3 quarters · filed 2024-02-09 | 5.35M shares derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-12-31 | 2.15M shares derived: 8-K 12 month − 10-Q 9 month · filed 2024-02-09 | 2.60M shares derived: sum of 2 quarters · filed 2024-02-09 | 3.36M shares derived: sum of 3 quarters · filed 2024-02-09 | 7.96M shares 8-K · filed 2024-02-09 |
| 2022-09-30 | 451.02K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 1.21M shares derived: sum of 2 quarters · filed 2022-11-10 | 5.81M shares 10-Q · filed 2022-11-10 | 5.93M shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 758.29K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 5.36M shares 10-Q · filed 2022-08-15 | 5.48M shares derived: sum of 3 quarters · filed 2022-08-15 | 5.59M shares derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | 4.60M shares 10-Q · filed 2022-05-13 | 4.72M shares derived: sum of 2 quarters · filed 2022-05-13 | 4.83M shares derived: sum of 3 quarters · filed 2022-05-13 | |
| 2021-12-31 | 113.98K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 231.17K shares derived: sum of 2 quarters · filed 2022-03-31 | 346.17K shares 10-K · filed 2022-03-31 | |
| 2021-09-30 | 117.19K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 232.19K shares 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | 115.00K shares 10-Q · filed 2021-09-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |